Here, we demonstrate that YK-4-279 in vitro anti-cancer efficacy is distinctly enhanced by P53 deletion in an ETS fusion-negative, but BRAFV600E-positive, colon cancer background. This evidence concerns the gene TP53 and colonic neoplasm.